Skip to main content

MEJORA DE LAS PROPIEDADES BIOQUIMICAS DE RETROTRANSCRIPTASAS DEL VIH, UTILES EN APLICACIONES BIOTECNOLOGICAS

PID2019-104176RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses

  • Huang, Tianguang
  • Sun, Lin
  • Kang, Dongwei
  • Poongavanam, Vasanthanathan
  • Liu, Xinyong
  • Zhan, Peng
  • Menéndez-Arias, Luis
Recent coronavirus outbreaks of SARS-CoV-1 (2002–2003), MERS-CoV (since 2012), and SARS-CoV-2 (since the end of 2019) are examples of how viruses can damage health care and generate havoc all over the world. Coronavirus can spread quickly from person to person causing high morbidity and mortality. Unfortunately, the antiviral armamentarium is insufficient to fight these infections. In this chapter, we provide a detailed summary of the current situation in the development of drugs directed against pandemic human coronaviruses. Apart from the recently licensed remdesivir, other antiviral agents discussed in this review include molecules targeting viral components (e.g., RNA polymerase inhibitors, entry inhibitors, or protease inhibitors), compounds interfering with virus-host interactions, and drugs identified in large screening assays, effective against coronavirus replication, but with an uncertain mechanism of action., Financial support from the Key Project of NSFC for International Cooperation (No. 81420108027), and the Key Research and Development Project of Shandong Province (No. 2017CXGC1401, 2019JZZY021011, 2020SFXGFY08) are gratefully acknowledged. Work in Madrid was supported by grants of the Ministry of Science and Innovation of Spain (PID2019-104176RB-I00/AEI/10.13039/501100011033) and CSIC (2019AEP001). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

An Update on Antiretroviral Therapy

  • Menéndez-Arias, Luis
  • Martín-Alonso, Samara
  • Frutos-Beltrán, Estrella
Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) still claim many lives across the world. However, research efforts during the last 40 years have led to the approval of over 30 antiretroviral drugs and the introduction of combination therapies that have turned HIV infection into a chronic but manageable disease. In this chapter, we provide an update on current available drugs and treatments, as well as future prospects towards reducing pill burden and developing long-acting drugs and novel antiretroviral therapies. In addition, we summarize efforts to cure HIV, including pharmaceutical strategies focused on the elimination of the virus., This work was supported by grants of the Ministry of Science and Innovation of Spain (BIO2016-76716-R (AEI/FEDER, UE) and PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A.), and CSIC (2019AEP001 awarded to L.M.-A.). S.M.-A. is a predoctoral fellow of the Ministry of Science and Innovation of Spain (BES-2017-079836). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings

  • Matl, Martin
  • Kellner, Max J.
  • Ansah, Felix
  • Grishkovskaya, Irina
  • Handler, Dominik
  • Heinen, Robert
  • Bauer, Benedikt
  • Menéndez-Arias, Luis
  • Auer, Thomas O.
  • Prieto-Godino, Lucia L.
  • Penninger, Josef M.
  • Vienna Covid-19 Detection Initiative (VCDI)
  • Awandare, Gordon A.
  • Brennecke, Julius
  • Pauli, Andrea
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests especially in low- and middle-income countries. Here, we developed an open-source Reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for the detection of respiratory RNA virus infections. It is based on non-proprietary enzymes, namely HIV-1 reverse transcriptase, Bst LF DNA polymerase and UDG BMTU thermolabile uracil DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our open-source lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared to the gold standard Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease-of-use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings., M.M. and M.J.K. were supported by the Vienna Science and Technology Fund (WWTF) through project COV20-031. This project received funding from the VW foundation (grant # 9A027) given to TReND in Africa, as well as funding from the "Mila Charitable Organisation". The IMP receives generous institutional funding from Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG852936), and IMBA is generously supported by the Austrian Academy of Sciences. Research in the lab of A.P. was supported by the Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80). Research in the lab of J.B. was supported by the European Research Council (ERC2015-CoG - 682181). F.A and G.A.A. were supported by a Science for Africa Foundation (SFA)/Wellcome Developing Excellence in Leadership Training and Science (DELTAS) in Africa grant (DEL-22-014: Awandare, G). Work in the L.M.-A. laboratory was supported by grant PID2019104176RBI00/AEI/10.13039/501100011033 of the Spanish Ministry of Science and Innovation, and an institutional grant of the Fundación Ramón Areces. The laboratory of J.M.P. at IMBA received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Swedish Research Council (2018- 05766), the T. von Zastrow foundation, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA., No